Obalon Therapeutics (NASDAQ:OBLN) issued its quarterly earnings results on Thursday. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.24), MarketWatch Earnings reports. Obalon Therapeutics had a negative return on equity of 115.36% and a negative net margin of 694.12%. The business had revenue of $0.70 million for the quarter.
Shares of Obalon Therapeutics stock opened at $0.68 on Friday. Obalon Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $5.97. The business’s fifty day moving average is $0.77 and its two-hundred day moving average is $1.09. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.17 and a quick ratio of 1.97.
Obalon Therapeutics Company Profile
Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.
Featured Story: What is a bull market?
Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.